Company intelligence / Profile preview

Amphasys AG

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Amphasys AG develops and markets innovative label-free single-cell analysis solutions based on patented impedance flow cytometry. Their products enable rapid assessment of cell size, morphology, viability, metabolic state etc., with major adoption in plant breeding/seed production industries for pollen quality control. The company’s platform also finds use across cellular agriculture and regenerative medicine research. They are recognized market leaders especially within pollen analytics.

Industry: Non-Drug Biotech

Partnerships

Bayer Crop ScienceEnza Zaden

Beyond the preview

Go deeper on Amphasys AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amphasys AG.

Explore the full profile